PL404138A1 - Benzoic acid derivatives as IL-15Rα receptor inhibitors - Google Patents

Benzoic acid derivatives as IL-15Rα receptor inhibitors

Info

Publication number
PL404138A1
PL404138A1 PL404138A PL40413813A PL404138A1 PL 404138 A1 PL404138 A1 PL 404138A1 PL 404138 A PL404138 A PL 404138A PL 40413813 A PL40413813 A PL 40413813A PL 404138 A1 PL404138 A1 PL 404138A1
Authority
PL
Poland
Prior art keywords
benzoic acid
acid derivatives
receptor inhibitors
overproduction
tautomers
Prior art date
Application number
PL404138A
Other languages
Polish (pl)
Inventor
Katarzyna Koziak
Barbara Żyżyńska-Granica
Sławomir Filipek
Szymon Niewieczerzał
Bartosz Trzaskowski
Oliwia Zegrocka-Stendel
Małgorzata Dutkiewicz
Piotr Krzeczyński
Elżbieta Kaczmarek
Magdalena Winiarska
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Priority to PL404138A priority Critical patent/PL404138A1/en
Priority to PCT/IB2014/000894 priority patent/WO2014191822A1/en
Publication of PL404138A1 publication Critical patent/PL404138A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Wynalazek dotyczy zastosowania pchodnych kwasu benzoesowego o wzorze (I), ich tautomerów, izomerów, farmaceutycznie dopuszczalnych soli i solwatów, do zapobiegania i leczenia chorób, u podłoża których leży nadprodukcja interleukiny 15.The invention relates to the use of the benzoic acid derivatives of formula (I), their tautomers, isomers, pharmaceutically acceptable salts and solvates, for the prevention and treatment of diseases which are the cause of overproduction of interleukin.

PL404138A 2013-05-31 2013-05-31 Benzoic acid derivatives as IL-15Rα receptor inhibitors PL404138A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL404138A PL404138A1 (en) 2013-05-31 2013-05-31 Benzoic acid derivatives as IL-15Rα receptor inhibitors
PCT/IB2014/000894 WO2014191822A1 (en) 2013-05-31 2014-05-29 BENZOIC ACID DERIVATIVES AS IL-15Rα RECEPTOR INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL404138A PL404138A1 (en) 2013-05-31 2013-05-31 Benzoic acid derivatives as IL-15Rα receptor inhibitors

Publications (1)

Publication Number Publication Date
PL404138A1 true PL404138A1 (en) 2014-12-08

Family

ID=51257533

Family Applications (1)

Application Number Title Priority Date Filing Date
PL404138A PL404138A1 (en) 2013-05-31 2013-05-31 Benzoic acid derivatives as IL-15Rα receptor inhibitors

Country Status (2)

Country Link
PL (1) PL404138A1 (en)
WO (1) WO2014191822A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
US11278505B2 (en) 2017-04-24 2022-03-22 University Of Massachusetts Diagnosis and treatment of vitiligo

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4436127A1 (en) * 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Use of benzoic or pyridine:carboxylic acid or amide cpds.
US6924308B1 (en) * 1997-07-30 2005-08-02 Howard L. Elford Therapeutic process for inhibiting NF-κB
US20120178697A9 (en) * 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
CU23472A1 (en) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech ANTAGONIST PEPTIDE OF INTERLEUCINE-15
DE102005005399A1 (en) * 2005-02-05 2006-08-10 Lts Lohmann Therapie-Systeme Ag Use of 2,4-dihydroxy-3-methylbenzoate derivatives for preparing medicaments or as basic substance for the development of other agents used for treating benign prostate hyperplasia, prostate carcinoma or spinobulbar muscular atrophy
CN100427082C (en) * 2005-08-02 2008-10-22 盛华（广州）医药科技有限公司 Application of hydroxybenzoate and analogue thereof in preparing medicament for preventing and treating viral infection
PT2054045E (en) * 2006-08-16 2011-08-31 Action Medicines Sl USE OF 2,5-DIHYDROXYBENZEN DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN
US7867989B2 (en) * 2007-06-22 2011-01-11 Vinitha Moolchand Thadani α-glucosidase inhibitors from lichens
US20110257177A1 (en) * 2008-09-22 2011-10-20 Calcimedica, Inc. Benzylthiotetrazole inhibitors of store operated calcium release
CU23716A1 (en) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech ANTAGONIST PEPTIDE OF THE ACTIVITY OF INTERLEUCINA-15
US8785499B2 (en) * 2009-07-10 2014-07-22 University Of Maryland, Baltimore Targeting NAD biosynthesis in bacterial pathogens

Also Published As

Publication number Publication date
WO2014191822A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
EA201691803A1 (en) HUMAN PLASMA KALLIKREIN INHIBITORS
JOP20190174B1 (en) Selective JAK1 inhibitors
MD20160106A2 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as IRAK4 inhibitors
EA201590224A1 (en) IMIDAZOTRIASINCARBONITRILE USED AS KINASE INHIBITORS
MX2017003695A (en) Pyrimidinones as factor xia inhibitors.
MX382991B (en) ARGININE METHYLTRANSFERASE INHIBITORS AND THEIR USES.
MY199894A (en) Prmt5 inhibitors and uses thereof
EA201591360A1 (en) AZABENZIMADAZLES AS INHIBITORS INHIBITORS PDE4 FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS
EA201692249A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
UA113160C2 (en) IL17 AND IFN-GAMMA INHIBITION FOR TREATMENT OF AUTOIMMUNE INFLAMMATION
UA110048C2 (en) IL17 INHIBITION AND IFN-GAMMA FOR TREATMENT OF AUTOIMMUNE INFLAMMATION
EA201791289A1 (en) INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
MX2018005004A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof.
EA201791480A1 (en) NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHARMONAL AGENTS
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
EA201990313A1 (en) DERIVATIVE TRIAZOLOPYRAZINONE USED AS A HUMAN PDE1 INHIBITOR
EA201500736A1 (en) PYRAZOLILKARBOXAMIDA I AS CRAC CHANNEL INHIBITORS
SA521421098B1 (en) -H4 Pyridopyrimidines as histamine receptor inhibitors
EA201500737A1 (en) PYRAZOLILKARBOXAMIDA II AS CRAC CHANNEL INHIBITORS